Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16014359 | 0.87 | P2RX7 (0.41) | NPBWR1P2RX3P2RX7MCHR1DCTPP1 | |
| SCHEMBL16014805 | 0.87 | P2RX7 (0.43) | NPBWR1P2RX3P2RX7MCHR1DCTPP1 | |
| SCHEMBL16023925 | 0.86 | NPBWR1 (0.40) | NPBWR1P2RX3P2RX7MCHR1DCTPP1 | |
| SCHEMBL16014737 | 0.84 | NPBWR1 (0.41) | NPBWR1P2RX3P2RX7MCHR1 | |
| SCHEMBL16014625 | 0.81 | P2RX7 (0.48) | NPBWR1P2RX7MCHR1 | |
| SCHEMBL16014593 | 0.79 | P2RX7 (0.42) | NPBWR1P2RX3P2RX7MCHR1DCTPP1 | |
| SCHEMBL16014856 | 0.76 | P2RX7 (0.44) | NPBWR1P2RX3P2RX7MCHR1DCTPP1 | |
| SCHEMBL16014473 | 0.75 | PTGS1 (0.44) | NPBWR1MCHR1DCTPP1 | |
| SCHEMBL16014705 | 0.74 | P2RX7 (0.47) | NPBWR1P2RX3P2RX7BUB1 | |
| SCHEMBL16014562 | 0.73 | P2RX7 (0.41) | NPBWR1P2RX3P2RX7MCHR1BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964626-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014135472-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135472-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002180-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | NPBWR1 3843/4885P2RX3 1860/4885P2RX7 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.